Overview
In this article, Michael Siekman and Brennen Baylor analyze the value of manufacturing patents for biologics and why companies should reevaluate their patent prosecution strategy.
Pharma Sector Should Push Manufacturing Patents for Biologics
-
CapabilitiesCapabilities
-
ServicesServices
- Antitrust
- Business Restructuring
- Corporate & Transactional
- Crisis Management
- Employee Benefits & Executive Compensation
- Employment
- Global Privacy & Cybersecurity
- Global White-Collar & Government Investigations
- Government & Lobbying Strategies
- Government Contracts
- Intellectual Property
- International Trade
- Investment Management
- Litigation & Dispute Resolution
- Private Client & Wealth Management
- Real Estate
- Shareholder Activism
- Strategic Solutions
- Sustainability, Impact & ESG
- Tax
- Trade Secrets
-
-
-
InsightsInsightsALL INSIGHTS
-
ResourcesResources
- Al in Healthcare Law Center
- Alcohol M&A Resource Center
- Artificial Intelligence Law Center
- CORA
- Cross-Border Investment
- Dawn Raid Guide
- Direct Primary Care Arrangements
- Freelancer Compliance Check
- GESC
- Global Privacy & Cybersecurity Resource Center
- Health Transactions Law Center
- Information Blocking & Interoperability in Healthcare
- Investing in Healthcare Resource Center
- McDermott University | On-Demand CLE
- Navigating the New Energy Landscape Resource Center
- No Surprises Act Resource Center
- SECURE 2.0 Act
- Unified Patent Court Resource Center
- US Policy Watch
-
-